ReviewDie Ophthalmologie2026
[Bardet-Biedl syndrome-diagnosis, care and treatment approaches].
Review in Die Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The Bardet-Biedl syndrome (BBS) is a genetically determined multiorgan disorder characterized by congenital postaxial polydactyly, obesity, hyperphagia and retinal dystrophy that develops in childhood. The condition is heterogeneous both in terms of molecular genetics and clinically: it is caused by mutations in at least 26 genes, and the variable extraocular manifestations include developmental delay, diabetes mellitus and fatty liver. The retinal dystrophy is also heterogeneous and presents with a broad phenotypic spectrum. While there is no specific treatment option for the retinal dystrophy, an approved treatment exists for the hyperphagia-related obesity. In addition to primary care, BBS patients should receive interdisciplinary care at specialized centers. Since 2026, patients with BBS1-associated retinal dystrophy are being enrolled in an ocular gene therapy study to evaluate the preliminary safety and tolerability of AXV-101.
Indexed as
Identifiers
42905171What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.